In the last trading session, 1.16 million shares of the ProKidney Corp (NASDAQ:PROK) were traded, and its beta was 1.50. Most recently the company’s share price was $0.86, and it changed around -$0.13 or -13.02% from the last close, which brings the market valuation of the company to $251.11M. PROK currently trades at a discount to its 52-week high of $3.00, offering almost -248.84% off that amount. The share price’s 52-week low was $0.46, which indicates that the current value has risen by an impressive 46.51% since then. We note from ProKidney Corp’s average daily trading volume that its 10-day average is 0.59 million shares, with the 3-month average coming to 791.04K.
ProKidney Corp stock received a consensus recommendation rating of Buy, based on a mean score of 2.20. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 3 recommended PROK as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight.
ProKidney Corp (NASDAQ:PROK) trade information
Instantly PROK has showed a red trend with a performance of -13.02% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.0500 on recent trading dayincreased the stock’s daily price by 18.1%. The company’s shares are currently down -49.24% year-to-date, but still down -14.21% over the last five days. On the other hand, ProKidney Corp (NASDAQ:PROK) is 6.36% up in the 30-day period. We can see from the shorts that 16.52 million shares have been sold at a short interest cover period of 26.84 day(s).
The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to increase their stock price by 82.8% from its current value. Analyst projections state that PROK is forecast to be at a low of $3 and a high of $6.
ProKidney Corp earnings are expected to increase by 9.74% in 2025, but the outlook is negative -2.31% per year for the next five years.
PROK Dividends
ProKidney Corp’s next quarterly earnings report is expected to be released on 2025-May-11.
ProKidney Corp (NASDAQ:PROK)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 30.05% of ProKidney Corp shares, and 41.88% of them are in the hands of institutional investors. The stock currently has a share float of 59.87%. ProKidney Corp stock is held by 101.0 institutions, with MORGAN STANLEY being the largest institutional investor. By 2024-06-30, it held 19.034% of the shares, which is about 14.45 million shares worth $35.54 million.
SUVRETTA CAPITAL MANAGEMENT, LLC, with 12.306% or 9.34 million shares worth $22.98 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
